D'Acquisto Fulvio, Merghani Ahmed, Lecona Emilio, Rosignoli Guglielmo, Raza Karim, Buckley Christopher D, Flower Roderick J, Perretti Mauro
William Harvey Research Institute, Bart's and The London, Queen Mary School of Medicine and Dentistry, UK.
Blood. 2007 Feb 1;109(3):1095-102. doi: 10.1182/blood-2006-05-022798. Epub 2006 Sep 28.
Annexin-1 is an anti-inflammatory protein that plays an important homeostatic role in innate immunity; however, its potential actions in the modulation of adaptive immunity have never been explored. Although inactive by itself, addition of annexin-1 to stimulated T cells augmented anti-CD3/CD28-mediated CD25 and CD69 expression and cell proliferation. This effect was paralleled by increased nuclear factor-kappaB (NF-kappaB), nuclear factor of activated T cells (NFATs), and activator protein-1 (AP-1) activation and preceded by a rapid T-cell receptor (TCR)-induced externalization of the annexin-1 receptor. Interestingly, differentiation of naive T cells in the presence of annexin-1 increased skewing in Th1 cells; in the collagen-induced arthritis model, treatment of mice with annexin-1 during the immunization phase exacerbated signs and symptoms at disease onset. Consistent with these findings, blood CD4+ cells from patients with rheumatoid arthritis showed a marked up-regulation of annexin-1 expression. Together these results demonstrate that annexin-1 is a molecular "tuner" of TCR signaling and suggest this protein might represent a new target for the development of drugs directed to pathologies where an unbalanced Th1/Th2 response or an aberrant activation of T cells is the major etiologic factor.
膜联蛋白-1是一种抗炎蛋白,在固有免疫中发挥重要的稳态作用;然而,其在调节适应性免疫中的潜在作用从未被探索过。尽管膜联蛋白-1本身无活性,但将其添加到受刺激的T细胞中可增强抗CD3/CD28介导的CD25和CD69表达以及细胞增殖。这种效应与核因子-κB(NF-κB)、活化T细胞核因子(NFATs)和活化蛋白-1(AP-1)的活化增加平行,并且在膜联蛋白-1受体由T细胞受体(TCR)诱导快速外化之后出现。有趣的是,在膜联蛋白-1存在的情况下,初始T细胞的分化增加了向Th1细胞的偏移;在胶原诱导的关节炎模型中,在免疫阶段用膜联蛋白-1治疗小鼠会加剧疾病发作时的体征和症状。与这些发现一致,类风湿性关节炎患者的血液CD4+细胞显示膜联蛋白-1表达明显上调。这些结果共同表明,膜联蛋白-1是TCR信号传导的分子“调节器”,并表明该蛋白可能代表针对Th1/Th2反应失衡或T细胞异常活化是主要病因的病理状况开发药物的新靶点。